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Introduction: Arthritic diseases are characterized by the degradation of collagenous and noncollagenous
extracellular matrix (ECM) components in articular cartilage. The increased expression and activity of matrix
metalloproteinases (MMPs) is partly responsible for cartilage degradation. This study used proteomics to identify
inflammatory proteins and catabolic enzymes released in a serum-free explant model of articular cartilage
stimulated with the pro-inflammatory cytokine interleukin 1β (IL-1β). Western blotting was used to quantify the
release of selected proteins in the presence or absence of the cyclooxygenase-2 specific nonsteroidal pro-inflammatory
drug carprofen.
Methods: Cartilage explant cultures were established by using metacarpophalangeal joints from horses euthanized for
purposes other than research. Samples were treated as follows: no treatment (control), IL-1β (10 ng/ml), carprofen
(100 μg/ml), and carprofen (100 μg/ml) + IL-1β (10 ng/ml). Explants were incubated (37°C, 5% CO2) over twelve day
time courses. High-throughput nano liquid chromatography/mass spectrometry/mass spectrometry uncovered
candidate proteins for quantitative western blot analysis. Proteoglycan loss was assessed by using the
dimethylmethylene blue (DMMB) assay, which measures the release of sulfated glycosaminoglycans (GAGs).
Results: Mass spectrometry identified MMP-1, -3, -13, and the ECM constituents thrombospondin-1 (TSP-1) and
fibronectin-1 (FN1). IL-1β stimulation increased the release of all three MMPs. IL-1β also stimulated the fragmentation of
FN1 and increased chondrocyte cell death (as assessed by β-actin release). Addition of carprofen significantly decreased
MMP release and the appearance of a 60 kDa fragment of FN1 without causing any detectable cytotoxicity to
chondrocytes. DMMB assays suggested that carprofen initially inhibited IL-1β-induced GAG release, but this effect was
transient. Overall, during the two time courses, GAG release was 58.67% ± 10.91% (SD) for IL-1β versus 52.91% ± 9.35%
(SD) with carprofen + IL-1β.
Conclusions: Carprofen exhibits beneficial anti-inflammatory and anti-catabolic effects in vitro without causing any
detectable cytotoxicity. Combining proteomics with this explant model provides a sensitive screening system for
anti-inflammatory compounds.* Correspondence: ali.mobasheri.manuscripts@gmail.com
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Articular cartilage is a highly specialized load-bearing tis-
sue that covers the ends of long bones in synovial joints
and provides a strong and resilient surface for smooth and
frictionless articulation as well as cushioning of the under-
lying bone [1,2]. The major biologic constituents of the
extracellular matrix (ECM) of cartilage include collagens,
proteoglycans, and noncollagenous proteins [1]. The
chondrocyte is the main cell type found within the ECM
of skeletally mature cartilage [3]. Chondrocytes synthesize
all the ECM components in cartilage [3] and maintain this
macromolecular framework in response to biochemical
and biomechanical stimuli [4]. The ECM contains a spe-
cific combination of structural proteins and glycoproteins
that are unique to cartilage. In addition, the ECM contains
a number of other smaller noncollagenous proteins,
including thrombospondin 1 (TSP-1) and fibronectin 1
(FN1). Fragments of FN1 are released in osteoarthritis
(OA) and are thought to promote further cartilage degra-
dation by upregulating catabolic signaling [5,6].
In diseases such as OA and rheumatoid arthritis (RA)
chondrocytes are targeted, via specific cell-surface cyto-
kine receptors, by pro-inflammatory cytokines such as
interleukin-1β (IL-1β) and tumour necrosis factor-α
(TNF-α). Although other pro-inflammatory cytokines (i.e.
IL-6, IL-8 and IL-17) are involved, IL-1β and TNF-α are
the predominant pro-inflammatory and catabolic cytokines
involved in joint disease initiation and progression [7,8].
These pro-inflammatory cytokines suppress collagen andCartilage shavings collected from  
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Figure 1 Schematic overview of the experimental design used in this
treatments before conditioned supernatant was removed and treatment reproteoglycan synthesis and drive inflammatory signaling,
and protease expression/activation [9].
Previous studies from our research group have used an
explant model of articular cartilage to study the major
proteins released in response to IL-1β stimulation [10].
Subsequent high-throughput MS analysis of this model
identified qualitative differences in MMP-1, -3, and -13
expression between untreated and IL-1β-stimulated ex-
plants in the spent culture media [11]. In this study,
we used high-throughput proteomics and quantitative
western blotting to evaluate the release of these MMPs
in response to IL-1β stimulation in the presence and
absence of carprofen (marketed as Rimadyl) [12], a non-
steroidal anti-inflammatory drug (NSAID) developed by
Pfizer Animal Health. Carprofen is a selective cyclooxy-
genase 2 (COX-2) inhibitor capable of blocking synthesis
of the key inflammatory bioactive lipids like prostaglan-
din E2 (PGE2). It is used clinically to provide 24-hour
relief of pain and inflammation in geriatric dogs and
horses with joint pain, OA, hip dysplasia, and other
forms of joint disease. The principal hypothesis of this
study was that by combining proteomics with western
blotting, we could determine and characterize effects of
anti-inflammatory compounds (by using carprofen as an
anti-inflammatory agent) in an in vitro model of cartil-
age (Figure 1). MMP-1, -3, and -13 were studied as sur-
rogate in vitro biomarkers of inflammation to determine
whether carprofen has the capacity to reduce the release
of these catabolic enzymes. The effect of carprofen on diameter explant discs cut and placed in 1 ml 
e DMEM to establish explant cultures.
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study. Explant cultures were incubated for 6 days in designated
plenished for cultures up to 12 days.
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cultures up to 6 and 12 days.
Methods
Animal tissues and statement of ethical approval
The animals used in this study were sourced from two
UK-based abattoirs. Animals were euthanized for non-
research purposes, having been stunned before slaughter
in accordance with Welfare of Animals (Slaughter or
Killing) Regulations 1995 [13]. Approval for the use of
abattoir-derived animal tissues was obtained from the
local Ethical Review Committee (Ethics Committee of
the School of Veterinary Science and Medicine) with
input from members of the University of Nottingham
Animal Welfare and Ethical Review Body (AWERB).
Cartilage dissection and explant culture
Macroscopically normal articular cartilage samples were
obtained from weight-bearing regions of the metacarpo-
phalangeal joints of horses of mixed breed, age, and sex.
Articular cartilage was harvested from the metacarpo-
phalangeal joints. The joints were first shaved to remove
excess hair and disinfected by washing with Hibiscrub and
then Trigene, before being soaked in bleach for 1 hour.
Afterward, the skin and flexor tendon was carefully re-
moved from the joint without breaking into the synovial
structure. A sterile scalpel was used to open the joint,
which was then washed with sterile PBS (Gibco). Articular
cartilage shavings of equal thickness were taken from the
end surface of the third metacarpal and placed in 50 ml of
serum-free DMEM (Thermo Scientific) + 4% Pen/Strep
(Sigma) (Penicillin/Streptomycin solution: (5,000 units/ml
penicillin, 5 mg/ml streptomycin)) (pre-warmed to 37°C).
These cartilage shavings were transferred to a Falcon tube
containing washing solution (sterile PBS + 10% Pen/Strep)
and were twice washed with rotation for 20 minutes.
Cartilage-explant discs were prepared by using a
3-mm biopsy punch (Kai Medical), with discs placed
into wells (five discs per 1 ml DMEM+ 2% Pen/Strep)
before incubation for 24 hours (37°C, 5% CO2). After
this equilibration period, media was removed and re-
placed with treatment media required for the purposes
of the experiment. Once explants had been treated and
incubated for the desired 6-day time courses, the super-
natants and cartilage explants were placed in labeled
Eppendorf tubes and stored at −80°C. Protease inhibitors
(Sigma) were added to the supernatant samples at the
time of removal and storage.
Time course
After dissection and explant culture protocols were
followed, wells (five explants discs with 1 ml culture
media) were set up for each of the following treatments:
untreated culture media (control), IL-1β (10 ng/ml),carprofen (100 μg/ml), or carprofen (100 μg/ml) + IL-1β
(10 ng/ml). Explants were incubated (37°C, 5% CO2) for
6 days before removal and storage of supernatants and
the addition of fresh treatment media. This process was
repeated to provide a time course with two assay points:
0 to 6 days and 6 to 12 days. This experimental set-up
was completed with cartilage from three animals, with
three replicates of each treatment from each animal.
NanoLC-MS/MS
MS analysis was completed on four culture supernatants
after 6 days of incubation: two from one animal (untreated
control and IL-1β stimulated) and two from a pool of
supernatants from three animals (untreated control and
IL-1β stimulated). To prepare samples for MS, reduction
of disulfide bonds was performed by addition of DTT
(Bio-Rad) to a final concentration of 10 mM, followed
by vortexing and incubation at 37°C for 30 minutes.
Alkylation of thiol groups performed by addition of IAA
(Bio-Rad) to a 55 mM concentration, vortexed and
incubated for 45 minutes at 37°C (in the dark). Ice-cold
acetone (1.2 ml) (Fisher) was added and incubated at −20°C
for 1 hour, and then after centrifugation at 15,000 rcf for
5 minutes, the acetone was discarded. Proteins in the pel-
let were digested with 20 ng/μl trypsin gold (Promega) at
37°C overnight (16 hours). Trypsin digestion was termi-
nated by addition of formic acid at a final concentration of
0.1%. Samples were zip-tipped with C18 resin (Millipore)
by using 20 μl 50% methanol and 0.1% formic acid to
elute. Excess solvent was evaporated off by heating at
70°C, to leave 10 μl of samples, which was transferred to
glass vials ready to be loaded onto the nanoLC column.
For each sample, 5 μl was loaded and analyzed by
nanoLC-MS/MS on an amaZon ETD (Bruker). A flow
rate of 250 nl/min was used to separate peptides. Solution
A (100% H2O + 0.1% formic acid) and solution B (100%
ACN+ 0.1% formic acid) were set to create a gradient of
10% solution B to 30% solution B over the course of an
hour (0.3% per minute). From each MS scan, the five most
abundant peptides were selected for fragmentation.
MS data processing
Mascot Daemon was used to search the Swiss-Prot data-
base (all mammals) by submitting the .MGF files. The
search parameters were as follows: Instrument: ESI-TRAP,
peptide charge, 2+ and 3+ ions; peptide tolerance, 0.5 Da;
13C = 1; max missed cleavages = 1. Fixed modifications:
carbamidomethyl (C) and variable modifications: oxida-
tion (M). Individual ions Mascot scores above 42 indicated
identity or extensive homology. Only protein identifica-
tions with probability-based protein family mascot
MOWSE scores above the significant threshold of >42
(P < 0.05) were accepted and included if consistently iden-
tified in the specific treatments.
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For each sample, 10 μl collected culture supernatant was
added to 10 μl of Laemmli sample buffer (62.5 mM Tris–
HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% wt/vol bro-
mophenol blue) (Bio-Rad) containing dithiothreitol (DTT)
(Bio-Rad) 0.15M). Samples were heated for 5 minutes at
95°C before loading into a 15-well 10% acrylamide gel. To
reference protein molecular weights Precision Plus Pro-
tein Standards (Bio-Rad) were also loaded. A voltage of
120 V was applied until the dye front reached the bottom
of the gel.
Western blotting
Western blots on days 0 to 6 of incubation were com-
pleted in three animals. Each sample of 50 μl was
concentrated by lyophilization (Heraeus-Christ) before
resuspension in 20 μl Laemmli buffer (Bio-Rad) before
performing SDS-PAGE (see previous method). Positive
controls were prepared by crushing articular cartilage with
a mortar and pestle under liquid nitrogen, and sus-
ended in Laemmli buffer. After SDS-PAGE, gels were
electroblotted onto low-fluorescence PVDF membrane
(GE Healthcare) at 80 V for 2 hours. Membranes were
blocked for 1 hour with 5% BSA (Sigma) in PBS-Tween
20 (0.1%) (Fisher). Primary antibodies were diluted as re-
quired in blocking solution before overnight incubation at
4°C. Dilutions for primary antibodies were as follows:
MMP-1 (1:800 dilution, Aviva), MMP-3 (1:1,000 dilution,
Aviva), MMP-13 (1:1,000 dilution, Aviva), FN1 (1:1,000
dilution, Aviva), TSP1 (1:1,000, Abcam). The antibodies
from Aviva systems biology were specifically designed to
cross-react with multiple different species, including the
horse.
After the overnight primary incubation, membranes
were incubated with secondary antibodies for 1 hour. The
secondary antibodies used in this study were all HRP con-
jugated and diluted to appropriate working concentrations
by using 3% BSA blocking solution. Secondary antibodies
were either anti-rabbit (1:100,000 dilution, Bio-Rad) for
MMP-1, MMP-3, MMP-3, and FN1 primary antibodies or
anti-rabbit/mouse (1:40,000 dilution, Dako) for the TSP-1
primary antibody.
Ampliflu Red Western Blot Kit (Sigma) was used to stain
protein bands with red fluorescence, which was next de-
tected on an FX-Imager (Bio-Rad) by using Quantity One
software (Bio-Rad). Densitometry was performed on the
images obtained by using ImageJ (NIH). Statistical analysis
applying an unpaired t-test was completed, and the results
graphically displayed using GraphPad Prism 6.
Chondrocyte cell death in the cartilage explants was
monitored indirectly by using western blotting to detect
β-actin release by explant cultures as an indicator of cyto-
toxicity and cell lysis. We compared the release of β-actin
in untreated (control) cartilage explants and those thatwere stimulated with IL-1β, carprofen, and carprofen +
IL-1β. For this purpose, we used a primary antibody to
β-actin (1:7,000 dilution, Sigma) and a secondary anti-
mouse HRP conjugate (1:100,000 dilution, Cell Signaling).
DMMB assays
For evaluation of proteoglycan release, the metachro-
matic dye 1,9 dimethylmethylene blue (DMMB) was used
to quantify the amount of sulfated glycosaminoglycans
(GAGs) released into the medium. DMMB, papain, and
chondroitin sulfate standards (Sigma) were prepared ac-
cording to the method developed by Farndale et al. [14].
Supernatant samples were diluted to appropriate concen-
trations, to be within the accurate range (0 to 75 μg/ml) of
the standard curve. On a 96-well plate, 40 μl of blank pa-
pain solution (duplicate), each standard (duplicate) and
sample dilutions (triplicate) were added. Next, 200 μl of
DMMB solution was added to each well, before reading
the plate at 540 nm (spectrophotometer) within 10 mi-
nutes. To calculate the percentage of total GAG release,
corresponding explant discs were digested overnight by
incubating with papain solution at 60°C, before their GAG
content was measured, also by DMMB assay. Total GAG
release levels per well were calculated, before dividing the
total GAG release by measurements for individual super-
natant samples to provide the percentage GAG release in
response to various treatments. Measurements from three
animals (three replicates per treatment) were combined to
provide final values for each incubation period.
GraphPad Prism 6 software was used produce graphic
images and complete statistical analysis with one-way
ANOVA by using the Tukey multiple comparison test.
Results and discussion
Carprofen decreases IL-1β-stimulated MMP-1 release
Mass spectrometric analysis of explant cultures incubated
for 6 days identified MMP-1 in IL-1β-stimulated samples
analyzed from all the animals (Table 1). MMP-1 was not
identified by MS in untreated control samples. Untreated
samples and carprofen-only treatments did not produce
detected levels of MMP-1 by using western blot analysis.
Western blots of day-6 explant cultures treated with IL-1β
and IL-1β + carprofen contained protein bands at around
53 kDa, consistent with the predicted molecular mass of
MMP-1 (Figure 2A). Densitometry and statistical analysis
showed a significant decrease in IL-1β-stimulated MMP-1
release in response to carprofen treatment.
Carprofen decreases IL-1β-stimulated MMP-3 release,
whereas TSP-1 is unaffected
MMP-3 was identified in both untreated and IL-1β-
stimulated explant media (after 6 days of incubation) by
qualitative MS analysis (Table 1). The mascot scores
were considerably higher in IL-1β treatments compared
Table 1 Summary of proteins identified in untreated control and IL-1β-stimulated samples with qualitative
nanoLC-MS/MS
Protein Accession
number
Mascot scores
Individual animal
Untreated control
Pooled untreated
control
Individual animal
IL-1β stimulated
Pooled IL-1β
stimulated
ECM proteins
Cartilage oligomeric matrix protein COMP_BOVIN 4090 4763 7555 10590
Fibronectin FINC_BOVIN 4422 6222 3786 3492
Chondroadherin CHAD_HUMAN 1022 3069 1978 3689
Thrombospondin 1 TSP1_BOVIN 741 1256 3456 2782
Aggrecan core protein PGCA_HUMAN 1815 3389 2258 6412
Decorin PGS2_HORSE 665 802 513 1130
Biglycan PGS1_HORSE 1099 1062 2047 1720
Fibromodulin FMOD_HUMAN 1307 3200 1381 1930
Collagen alpha-1(II) chain CO2A1_BOVIN 137 59 133 82
Collagen alpha-2(VI) chain CO6A2_HUMAN 190 79
Collagen alpha-1(X) chain COAA1_MOUSE 77 102
Prolargin PRELP_MOUSE 124 147 311 301
Cartilage intermediate-layer protein 1 (CILP-1) CILP1_MOUSE 201 789 423 264
Proteoglycan 4 (Lubricin) PRG4_HUMAN 139 49 59
SPARC (secreted protein acidic, cysteine rich) SPRC_PIG 108 96
Non-ECM secreted proteins
Clusterin CLUS_HORSE 2767 4723 1785 4876
Chitinase-3-like protein 1 (YKL-40) CH3L1_BOVIN 574 1178 414 2018
Serum amyloid A protein SAA_CANFA 43
SAA_HORSE 55 219 436
Metalloproteinase inhibitor 1 TIMP1_HORSE 83 312 457 146
Alpha-1-antiproteinase 2 A1AT2_HORSE 99 342 50
MMP-1 MMP1_HORSE 1678 1586
MMP-3 MMP3_HORSE 653 956 5441 4580
MMP-13 MMP13_HORSE 1700 699
TNF-R superfamily, member 11b (Osteoprotegerin) TR11B_RAT 252 319 388 638
Procollagen C-endopeptidase enhancer 2 PCOC2_HUMAN 163 171
Lysozyme C LYSM_BOVIN 72 168 179 148
Secreted frizzled-related protein 3 SFRP3_BOVIN 74 98
Lactadherin MFGM_PIG 83 63 54
Extracellular superoxide dismutase [Cu-Zn] SODE_HUMAN 67 72
Macrophage migration inhibitory factor MIF_HUMAN 91 86
Ribonuclease 4 RNAS4_HUMAN 48 46 59
Intracellular proteins
Vimentin VIME_PANTR 84
VIME_PIG 2361 3837
Alpha-enolase ENOA_BOVIN 506 686
Phosphoglycerate mutase 1 PGAM1_MOUSE 149 104
Phosphatidylethanolamine-binding protein 1 PEBP1_HUMAN 423 148
Phosphoglycerate kinase 1 PGK1_HORSE 792 651
Williams et al. Arthritis Research & Therapy 2013, 15:R223 Page 5 of 11
http://arthritis-research.com/content/15/6/R223
Table 1 Summary of proteins identified in untreated control and IL-1β-stimulated samples with qualitative
nanoLC-MS/MS (Continued)
Pyruvate kinase isoforms M1/M2 KPYM_HUMAN 488 245
Purine nucleoside phosphorylase PNPH_HUMAN 175 134
Glyceraldehyde 3-phosphate dehydrogenase G3P_PIG 208 115
Thioredoxin THIO_HORSE 145 143
Other
Serum albumin ALBU_BOVIN 283 86
Pancreatic trypsin inhibitor BPT1_BOVIN 283 477 281 703
Trypsin TRYP_PIG 111 106 746
Keratin, type II cytoskeletal 3 K2C3_RABIT 151 277 110
MMPs (-1, -3, and -13) were identified from this high-throughput proteomic analysis and investigated further in this study. Identifications were attained by using
Mascot Daemon to search the Swiss-Prot database (All mammals). Only peptide identifications with a probability-based protein family mascot MOWSE score above
the significant threshold of >42 (with a statistical significance level of P < 0.05) were included. MMPs (-1, -3, and -13) were identified from this high-throughput
proteomic analysis and investigated further in this study.
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stimulation was having an impact on MMP-3 release. Be-
cause the MS analysis was qualitative, western blotting
was used to provide accurate quantification of MMP-3
release.
Western blotting was used to quantify changes in
MMP-3 release from explants in response to IL-1β
stimulation and/or carprofen treatment. Upregulation of
MMP-3 and its increased proteolytic activity is known
to target several ECM substrates [15]. Western blotting
for TSP-1 was therefore carried out by using the same
membranes to determine whether the release of this
ECM protein is affected by IL-1β stimulation and car-
profen treatment. Bands for MMP-3 were visible at
different intensities at 54 kDa in all treatment groups.
An additional band a few kDa below 54 kDa appeared in
all samples stimulated with IL-1β. This lower band cor-
responds to the active form of MMP-3 from which the
propeptide domain has been cleaved.
Western blots of untreated and carprofen-alone sam-
ples revealed only a single band at 54 kDa corresponding
to the nonactive zymogen form of MMP-3 [16,17].
Comparisons of MMP-3 release in explant cultures
6-day incubations (n = 3) (Figure 2) provided evidence
to support the assertion that carprofen significantly de-
creases cytokine-stimulated MMP-3 release. MMP-
mediated degradation of the ECM may be inhibited by
carprofen, as treatment with this NSAID reduced the
IL-1β-stimulated release and activation of MMP-3.
TSP-1 blots produced expected bands around 125 kDa
that were visible in only IL-1β- and carprofen + IL-1β-
stimulated samples. Densitometry did not show any sig-
nificant differences in the presence of carprofen alone
(See Additional file 1: Figure S1).Carprofen decreases IL-1β-stimulated MMP-13 release
Release of MMP-13 was not detected by MS analysis of
untreated explant culture media. However, MMP-13 was
found in the media from all explant cultures stimulated
with IL-1β (Table 1). This suggests that MMP-13 release
was initiated in the explant model after IL-1β stimulation,
but western blotting was required for quantification.
MMP-13 release was increased by IL-1β stimulation,
and corresponding bands at 54 kDa were seen only in the
presence of this cytokine (that is, not in untreated or
carprofen-only explant cultures) (Figure 2). For IL-1β +
carprofen treatments, faint bands were present after
6 days of incubation. Significantly less MMP-13 release
occurred in the presence of carprofen when the IL-1β and
IL-1β + carprofen samples were compared.
Carprofen treatment decreases the IL-1β-stimulated
production of the 60 kDa fragment of FN1
Western blotting of FN revealed bands at 230 kDa repre-
senting the glycosylated monomer of this proteoglycan,
and a further band at 60 kDa (Figure 3). Stimulation with
IL-1β increased the density of the lower band (60 kDa),
suggesting that this is a degradation product induced by
this pro-inflammatory cytokine. A significant reduction
was noted in the intensity of this band when carprofen
was present along with the IL-1β.
Carprofen does not inhibit GAG release throughout the
entire time course
A significant increase in GAG release in IL-1β-stimulated
cultures was found compared with untreated controls
(Figure 4). Carprofen treatment alone did not have any
effect on the level of GAG release, as GAG levels were
similar to untreated explant cultures throughout the entire
Carprofen
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IL-1β
1     2     3 M
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1     2     3M +
75 kDa
Carprofen
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Figure 2 Western blotting of MMP-1, -3, and -13 release in the
secretome of cartilage explants in culture. (A) Representative
MMP-1 western blot image and densitometric analysis showing
significant decrease in IL-1β-stimulated release of MMP-1 in response
to carprofen treatment. (B) Representative MMP-3 western blot image
and densitometric analysis displaying the significant reduction of IL-1β
MMP-3 release attributed to carprofen treatment. (C) Representative
MMP-13 western blot image and densitometric analysis showing
significantly higher MMP-13 release in the presence of IL-1β alone,
compared with carprofen + IL-1β. All cartilage-explant supernatants
were incubated for 6 days. This experimental design was carried out
with tissues obtained from three separate animals, with three treatment
replicates from each animal (n = 9). Statistical analysis completed =
unpaired t-test. Treatments were as follows: untreated control, IL-1β
(10 ng/ml), carprofen (100 μg/ml), or carprofen (100 μg/ml) + IL-1β
(10 ng/ml). Error bars indicate standard deviation. ***P < 0.001. M,
molecular weight markers; +positive control.
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IL-1β with carprofen + IL-1β shows that carprofen caused
a significant decrease in GAG release. The later time point
of 6 to 12 days showed that carprofen + IL-1β had only
delayed the GAG release compared with IL-1β (Figure 4).
The degradation of the ECM in articular cartilage is
known to be facilitated by pro-inflammatory cytokines
such as IL-1β in degenerative joint diseases such as OA
[7,8]. Consequently, IL-1β is frequently used in culture
models of arthritis to mimic the environment present
within OA joints [18,19]. The use of physiologically rele-
vant tissue-culture models (Figure 1) can provide me-
chanistic insights into the inflammatory and catabolic
responses of cartilage by using tissues from euthanized
cadavers, reducing the need to use animal models. In this
study, we used IL-1β-stimulated cartilage explants in a
static culture system. We previously used a targeted high-
throughput proteomic approach to identify the major
proteins present in the secretome of articular cartilage
exposed to IL-1β [10,11].
Here we compared the effects of stimulation with IL-1β
in the presence and absence of carprofen. One of the
important issues addressed was the potential cytotoxic
effects of carprofen on chondrocytes within the cartilage
explants, especially because the culture system used was
serum free and involved long incubation periods. The
cytotoxicity of carprofen at 100 μg/ml was assessed by
monitoring β-actin release from the explants by using
western blotting. Western blot experiments with anti-
bodies to β-actin were used to demonstrate that chondro-
cytes within the explants did not undergo cell death and
lysis when treated with carprofen.
The data obtained indicated that IL-1β stimulation in-
creases β-actin release, but addition of carprofen alone
does not increase cytotoxicity compared with untreated
controls (see Additional file 2: Figure S2).
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Figure 3 IL-1β-stimulated degradation of FN1 and the
production of its 60 kDa fragment is significantly reduced after
carprofen + IL-1β treatment. (A) Representative FN western blot
image. The band at about 230 kDa represents the glycosylated FN
monomer. The 60 kDa band fragment was released when explants
were stimulated with IL-1β. (B) Graphic representation of densitometry
for FN. Explant cultures were completed for 6 days in three separate
animals, with three treatment replicates on each occasion (n = 9).
Explant treatments: untreated control, IL-1β (10 ng/ml), carprofen
(100 μg/ml), or carprofen (100 μg/ml) + IL-1β (10 ng/ml). Error bars
indicate standard deviation. An unpaired t-test was applied to assess
significance. ***P < 0.001.
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teins including MMP-1, MMP-3, and MMP-13 in the
secretome of IL-1β-stimulated samples (Table 1). These
proteins were then selected as markers for studying the
effects of carprofen. Treatment with carprofen resulted
in a qualitative reduction in the levels of these proteins,
even in the continued presence of IL-1β.
This qualitative approach also confirmed that MMP-1
and MMP-13 are found only above the identification
threshold in IL-1β-stimulated samples, compared with
untreated samples. Quantitative western blotting wasused to demonstrate that the released levels of all three
MMPs are significantly elevated after IL-1β stimulation.
IL-1β signaling initiates the active form of NF-κB,
causing transcription of pro-inflammatory and proa-
poptotic genes, initiating the release of various catabolic
enzymes, including aggrecanases, cathepsins, ADAMTS,
and MMPs (-1, -3, and -13) [20-22].
MMP-13 is a collagenase and has a major role in type
II collagen degradation [23,24]. It also has the ability to
degrade other collagens present in cartilage (types VI
and IX), aggrecan, and various other ECM proteoglycans
and constituents [25]. It has been identified in investiga-
tions into OA cartilage as a protein that is differentially
upregulated in OA [26,27]. The progression of OA has
been shown to be slowed by deletion of the MMP-13
gene in a MLI-induced OA mouse model [28]. MMP-1
is another member of the collagenase family that is
effective at cleaving collagen I, II, and III [29]. The en-
zyme is able to unwind the triple helix of α chains before
it cleaves collagen [29]. A quantitative analysis of chon-
drocytes has shown that IL-1β stimulation caused a sig-
nificant increase in MMP-1 secretion [30]. Expression of
the MMP-1 gene in equine articular cartilage has also
been shown to be upregulated by IL-1β and LPS intra-
articular injections [31]. MMP-3 (stromelysin-1) is
known to activate both MMP-1 and MMP-13 by cleav-
age of their propeptide domains [32], which will lead to
increased collagen degradation. In this study, we found
that MMP-3 was detectable in the untreated secretome,
but levels were significantly higher after IL-1β stimula-
tion. OA cartilage secretome has been show to contain
increasingly high levels of MMP-3 [33,34] and is shown
to be induced in cartilage and chondrocytes by proin-
flammatory cytokines [30,35,36].
Measurements of MMP-1, MMP-3, and MMP-13
within in vitro models of cartilage inflammation can be
used as screening systems for drugs and anti-inflammatory
compounds. Interestingly, the reduced levels of these
enzymes in the presence of carprofen suggests that this
NSAID has the capacity to inhibit MMP release and
activation and can be used as a reference drug in studies
investigating the effects of compounds with potential
anti-inflammatory properties. No previous proteomic
studies report the use of carprofen as an inhibitor of
MMP release and activity in explant cultures of cartilage
stimulated with IL-1β. Therefore, this study expands on
previous work in this area by testing the effects of car-
profen in a novel context [10]. Carprofen is commonly
used as a 24-hour treatment for arthritic dogs and is also
available for use in large animals, including horses. The
COX-2 enzyme is responsible for inducing metabolism
of arachidonic acid, leading to the production of various
prostaglandins, including PGE2, which contributes to
inflammatory signaling in synovial joint arthritis. It
Figure 4 Percentage GAG release throughout the time course with IL-1β stimulation and carprofen treatment. The following treatments
were applied: untreated control, IL-1β (10 ng/ml), carprofen (100 μg/ml) + IL-1β (10 ng/ml), or carprofen (100 μg/ml). The percentage GAG release
was measured after 0 to 6 days and 6 to 12 days of incubation. The day 6 GAG-release data confirmed that carprofen slows IL-1β-stimulated GAG
release. The GAG-release measurements for the day 12 time point would have been influenced by GAG loss during the earlier culture period.
Carprofen + IL-1β samples showed higher GAG release at day 12 than did IL-1β alone, because of the high loses that had already occurred during
days 0 to 6. Explant culture time courses were completed by using tissues from three separate animals, with three treatment replicates for each
experiment. **P < 0. 01; ***P < 0. 001. Error bars indicate standard deviation.
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carprofen in this explant model would attenuate the
inflammatory effects stimulated by IL-1β stimulation.
Significant decreases in the IL-1β-stimulated release of
active MMP-1, MMP-3, and MMP-13 were observed in
the presence of carprofen.
These findings suggest that as well as alleviating pain,
the use of this drug may help protect cartilage against
the catabolic effects of proteases and therefore afford a
certain level of protection against MMP activation and
ECM loss.
The involvement of MMP action in the progression of
OA has led to studies on the therapeutic effects of MMP
inhibitors. Joint damage, osteochondral angiogenesis,
and perceived pain were reduced by treatment with
MMP inhibitors in a rat meniscal transection model of
OA [37]. Whereas MMPs can contribute to collagen
degradation, ADAMTS is believed to be the main en-
zyme responsible for aggrecan, GAG, and proteoglycan
loss [38]. A DMMB assay measuring the GAG release in
the cartilage explant culture time course indicated that,
although inflammatory MMPs are significantly reduced
by carprofen, equivalent GAG release occurs when
comparing IL-1β and carprofen + IL-1β-treated explants
cultured for up to 12 days.
Conclusions
In summary, the cartilage explant model used here has
allowed us to use MMP-1, -3, and -13 as biomarkers to
study the anti-inflammatory and anti-catabolic effects of
carprofen. This may represent a useful approach for
screening putative anti-inflammatory drugs with added
anti-MMP activity in vitro and may be used for testingthe effects of naturally occurring compounds on MMP
expression in cartilage. This model also incorporates
important elements of the replacement, refinement, and
reduction of research by using animals (3Rs), thus pro-
viding an alternative to in vivo models of arthritis.
Additional files
Additional file 1: Figure S1. TSP-1 release stimulated by IL-1β is not
significantly decreased after carprofen + IL-1β treatment. Western blots for
TSP-1 produced a band at about 125 kDa that was detected only in the
presence of IL-1β. Cartilage explants were cultured for 6 days with three
treatment replicates from the same individual animal (n = 3). Explant
treatments: untreated control, IL-1β (10 ng/ml), carprofen (100 μg/ml), or
carprofen (100 μg/ml) + IL-1β (10 ng/ml).
Additional file 2: Figure S2. Cartilage explant cultures treated with
IL-1β or carprofen + IL-1β did not show significant differences in β-actin
release. (A) Representative western blot confirming the absence of
β-actin in explant cultures that were untreated or treated with carprofen
alone. IL-1β and carprofen + IL-1β treatments induced β-actin release, as
evidenced by detection of an approximate 42 kDa band. (B) Graphic
representation of the densitometric analysis of β-actin bands. An
unpaired t-test was applied to assess statistical significance. ns, no
significant difference; +, positive control for β-actin (equine chondrocyte
lysate). Cartilage explants were cultured for 6 days with three treatment
replicates from two animals (n = 6). Explant treatments: untreated control,
IL-1β (10 ng/ml), carprofen (100 μg/ml), or carprofen (100 μg/ml) + IL-1β
(10 ng/ml).
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